Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
February 22 2023 - 5:28AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT
OF 1934
For the month of February 2023
--------------
Commission File Number: 001-32371
----------
SINOVAC BIOTECH LTD.
No. 39 Shangdi Xi Road
Haidian District
Beijing 100085, People’s
Republic of China
(Address of principal executive
offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
CONTENTS
Explanatory Note
On February 21, 2023, Sinovac Biotech Ltd. (the “Company”)
entered into a fourth amendment (the “Fourth Amendment”) to the Amended and Restated Rights Agreement, dated as of February
22, 2019 (the “Amended and Restated Rights Agreement”), as amended by the Amendment to the Amended and Restated Rights Agreement
dated as of February 19, 2020 (the “Amendment to Amended and Restated Rights Agreement”), by the Second Amendment to the Amended
and Restated Rights Agreement dated as of February 21, 2021 (the “Second Amendment to Amended and Restated Rights Agreement), and
by the Third Amendment to the Amended and Restated Rights Agreement dated as of February 21, 2022 (the “Third Amendment to Amended
and Restated Rights Agreement), between the Company and Pacific Stock Transfer Company, as Rights Agent, to extend the expiration date
of the rights contained therein from February 22, 2023 to February 22, 2024.
The foregoing summary of the Fourth Amendment is
qualified in its entirety by reference to the full text of the Fourth Amendment, which is filed as Exhibit 4.1 hereto and is incorporated
herein by reference. A copy of the Third Amendment to Amended and Restated Rights Agreement and a summary of its material terms were filed
with the SEC on Form 6-K on February 22, 2022 (incorporated herein by reference by Exhibit 4.2). A copy of the Second Amendment to Amended
and Restated Rights Agreement and a summary of its material terms were filed with the SEC on Form 6-K on February 22, 2021 (incorporated
herein by reference by Exhibit 4.3). A copy of the Amendment to Amended and Restated Rights Agreement and a summary of its material terms
were filed with the SEC on Form 6-K on February 21, 2020 (incorporated herein by reference by Exhibit 4.4). A copy of the Amended and
Restated Rights Agreement and a summary of its material terms were filed with the Securities and Exchange Commission on Form 6-K on February
22, 2019 (incorporated herein by reference by Exhibit 4.5).
Incorporation
by Reference
The
summary of the Fourth Amendment above and Exhibit 4.1 attached hereto are hereby incorporated by reference into our registration statements
on Form S-8 filed with the Securities and Exchange Commission on September 10, 2009 (File No. 333-161827) and Form S-8 filed with the
Securities and Exchange Commission on September 4, 2013 (File No. 333-190980).
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
SINOVAC BIOTECH LTD. |
|
|
|
|
|
|
|
By: |
/s/ Nan Wang |
|
Name: |
Nan Wang |
|
Title: |
Chief Financial Officer |
Date: February 22, 2023
Exhibit Index
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Apr 2024 to May 2024
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From May 2023 to May 2024